Please login to the form below

Not currently logged in
Email:
Password:

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

merck donald nicholsonNimbus has appointed Merck & Co's Donald Nicholson as the company's new CEO.

Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.

He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.

In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.

It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”

1st October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics